Lessons learned : A look back at the performance of nine COVID-19 serologic assays and their proposed utility
Copyright © 2023. Published by Elsevier Inc..
BACKGROUND: Serologic assays for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been proposed to assist with the acute diagnosis of infection, support epidemiological studies, identify convalescent plasma donors, and evaluate vaccine response.
METHODS: We report an evaluation of nine serologic assays: Abbott (AB) and Epitope (EP) IgG and IgM, EUROIMMUN (EU) IgG and IgA, Roche anti-N (RN TOT) and anti-S (RS TOT) total antibody, and DiaSorin (DS) IgG. We evaluated 291 negative controls (NEG CTRL), 91 PCR positive (PCR POS) patients (179 samples), 126 convalescent plasma donors (CPD), 27 healthy vaccinated donors (VD), and 20 allogeneic hematopoietic stem cell transplant (HSCT) recipients (45 samples).
RESULTS: We observed good agreement with the method performance claims for specificity (93-100%) in NEG CTRL but only 85% for EU IgA. The sensitivity claims in the first 2 weeks of symptom onset was lower (26-61%) than performance claims based on > 2 weeks since PCR positivity. We observed high sensitivities (94-100%) in CPD except for AB IgM (77%), EP IgM (0%). Significantly higher RS TOT was observed for Moderna vaccine recipients then Pfizer (p-values < 0.0001). A sustained RS TOT response was observed for the five months following vaccination. HSCT recipients demonstrated significantly lower RS TOT than healthy VD (p < 0.0001) at dose 2 and 4 weeks after.
CONCLUSIONS: Our data suggests against the use of anti-SARS-CoV-2 assays to aid in acute diagnosis. RN TOT and RS TOT can readily identify past-resolved infection and vaccine response in the absence of native infection. We provide an estimate of expected antibody response in healthy VD over the time course of vaccination for which to compare antibody responses in immunosuppressed patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:117 |
|---|---|
| Enthalten in: |
Clinical biochemistry - 117(2023) vom: 15. Juli, Seite 60-68 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tolan, Nicole V [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.06.2023 Date Revised 09.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clinbiochem.2023.03.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35384165X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35384165X | ||
| 003 | DE-627 | ||
| 005 | 20231226060934.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clinbiochem.2023.03.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1179.xml |
| 035 | |a (DE-627)NLM35384165X | ||
| 035 | |a (NLM)36878344 | ||
| 035 | |a (PII)S0009-9120(23)00043-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tolan, Nicole V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lessons learned |b A look back at the performance of nine COVID-19 serologic assays and their proposed utility |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.06.2023 | ||
| 500 | |a Date Revised 09.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Inc. | ||
| 520 | |a BACKGROUND: Serologic assays for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been proposed to assist with the acute diagnosis of infection, support epidemiological studies, identify convalescent plasma donors, and evaluate vaccine response | ||
| 520 | |a METHODS: We report an evaluation of nine serologic assays: Abbott (AB) and Epitope (EP) IgG and IgM, EUROIMMUN (EU) IgG and IgA, Roche anti-N (RN TOT) and anti-S (RS TOT) total antibody, and DiaSorin (DS) IgG. We evaluated 291 negative controls (NEG CTRL), 91 PCR positive (PCR POS) patients (179 samples), 126 convalescent plasma donors (CPD), 27 healthy vaccinated donors (VD), and 20 allogeneic hematopoietic stem cell transplant (HSCT) recipients (45 samples) | ||
| 520 | |a RESULTS: We observed good agreement with the method performance claims for specificity (93-100%) in NEG CTRL but only 85% for EU IgA. The sensitivity claims in the first 2 weeks of symptom onset was lower (26-61%) than performance claims based on > 2 weeks since PCR positivity. We observed high sensitivities (94-100%) in CPD except for AB IgM (77%), EP IgM (0%). Significantly higher RS TOT was observed for Moderna vaccine recipients then Pfizer (p-values < 0.0001). A sustained RS TOT response was observed for the five months following vaccination. HSCT recipients demonstrated significantly lower RS TOT than healthy VD (p < 0.0001) at dose 2 and 4 weeks after | ||
| 520 | |a CONCLUSIONS: Our data suggests against the use of anti-SARS-CoV-2 assays to aid in acute diagnosis. RN TOT and RS TOT can readily identify past-resolved infection and vaccine response in the absence of native infection. We provide an estimate of expected antibody response in healthy VD over the time course of vaccination for which to compare antibody responses in immunosuppressed patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 vaccination | |
| 650 | 4 | |a Convalescent plasma donors | |
| 650 | 4 | |a Coronavirus disease 2019 (COVID-19) | |
| 650 | 4 | |a Epidemiologic studies | |
| 650 | 4 | |a Estimate of expected antibody response | |
| 650 | 4 | |a Immunosuppressed patients | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 650 | 7 | |a Immunoglobulin A |2 NLM | |
| 700 | 1 | |a DeSimone, Mia S |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandes, Maria D |e verfasserin |4 aut | |
| 700 | 1 | |a Lewis, Joshua E |e verfasserin |4 aut | |
| 700 | 1 | |a Simmons, Daimon P |e verfasserin |4 aut | |
| 700 | 1 | |a Schur, Peter H |e verfasserin |4 aut | |
| 700 | 1 | |a Brigl, Manfred |e verfasserin |4 aut | |
| 700 | 1 | |a Tanasijevic, Milenko J |e verfasserin |4 aut | |
| 700 | 1 | |a Desjardins, Michaël |e verfasserin |4 aut | |
| 700 | 1 | |a Sherman, Amy C |e verfasserin |4 aut | |
| 700 | 1 | |a Baden, Lindsey R |e verfasserin |4 aut | |
| 700 | 1 | |a Snyder, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Melanson, Stacy Ef |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical biochemistry |d 1970 |g 117(2023) vom: 15. Juli, Seite 60-68 |w (DE-627)NLM000001988 |x 1873-2933 |7 nnns |
| 773 | 1 | 8 | |g volume:117 |g year:2023 |g day:15 |g month:07 |g pages:60-68 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clinbiochem.2023.03.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 117 |j 2023 |b 15 |c 07 |h 60-68 | ||